185997-26-6

Basic information

• Product Name: (1R,3aR,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-Methyloctahydro-1H-inden-4-ol
• Synonyms: (1R,3aR,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-Methyloctahydro-1H-inden-4-ol;(1R,3aR,7aR)-1-[(2S)-1-hydroxypropan-2-yl]-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-4-ol
• CAS NO: 185997-26-6
• Molecular Formula: C₁₃H₂₄O₂
• Molecular Weight: 212.32846
• Mol File: 185997-26-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 317.4±10.0 °C(Predicted)
• Appearance: /
• Density: 1.050±0.06 g/cm3(Predicted)
• PKA: 14.98±0.10(Predicted)
• CAS DataBase Reference: (1R,3aR,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-Methyloctahydro-1H-inden-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,3aR,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-Methyloctahydro-1H-inden-4-ol(185997-26-6)
• EPA Substance Registry System: (1R,3aR,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-Methyloctahydro-1H-inden-4-ol(185997-26-6)

Safety Data

• Hazardous Substances Data: 185997-26-6(Hazardous Substances Data)

Usage

General Description

The chemical "(1R,3aR,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-ol" is a stereoisomer of a compound that contains a hydroxyl group attached to a propan-2-yl group. It is a cyclohexane derivative with a hydroxyl group bound to a chiral carbon, and a methyl group attached to another chiral carbon. The compound has a unique three-dimensional structure and can exhibit different biological and chemical properties based on its stereochemistry. It may have potential applications in pharmaceuticals, natural products, or organic synthesis. Further study and experimentation are necessary to fully understand the properties and potential uses of this compound.

Upstream product

• 124905-24-4 De-A,B-8-Oxo-23,24-dinorcholan-22-ol 
• 50-14-6 Calciferol 

Downstream Products

• 1451188-52-5 C₄₅H₇₈O₆SSi₂ 
• 1192803-39-6 C₃₉H₇₂O₃Si₂ 
• 1477494-91-9 C₃₉H₇₂O₃Si₂ 
• 1263286-71-0 (7aR)-7a-methyl-1-((S)-1'-(phenylsulfonyl)propane-2'-yl)hexahydro-1H-inden-4(2H)-on 
• 1263286-76-5 (1R,3R,7E,22E,24E)-24a-homo-19-nor-9,10-secoergosta-5,7,22,24-tetraen-1,3,25-triol 
• 131918-61-1 paricalcitol 
• 132015-95-3 (1R,3R,7E,22E,24R)-24-methyl-19-nor-9,10-secocholesta-5,7,22-triene-1,3,25-triol 
• 1263286-72-1 (7E)-(1R,3R)-24-phenylsulfonyl-1,3-bis(tert-butyldimethylsililoxy)-9,10-seco-19,22,23-trinorchola-5,7-dien 
• 1263286-74-3 C₄₆H₇₆O₇SSi₂ 
• 1451188-49-0 C₄₀H₇₂O₃Si₂ 
• 1451188-50-3 C₄₂H₇₆O₃Si₂ 
• 1263286-75-4 (1R,3R,7E,22E,24E)-24a-homo-19-nor-9,10-secoergosta-5,7,22,24-tetraen-1,3,25-triol 
• 1402710-06-8 C₄₅H₇₈O₆SSi₂ 
• 215509-33-4 (2S)-2-((1R,3aR,7aR)-4-(tert-butyldimethylsilyloxy)-7a-methyloctahydro-1H-inden-1-yl)propan-1-ol 

Relevant articles and documents

A new metabolite of Paricalcitol: stereoselective synthesis of (22Z)-isomer of 1α,25-dihydroxy-19-norvitamin D2

Stereoselective synthesis of (22Z)-isomer of Paricalcitol, an analog of 1,25-dihydroxyergocalciferol, an active form of vitamin D2 (Ergocalciferol) has been described. The two key critical synthetic steps involved are Julia–Lythgoe's Wittig–Hor

Synthesis and crystallographic study of 1,25-dihydroxyergocalciferol analogs

The hybrid analogs of 1,25-dihydroxyergocalciferol (PRI-5201 and PRI-5202) were synthesized as potential anticancer agents using a convergent strategy. The analogs were designed by combining a 19-nor modification of the A-ring with the homologated and rig

Vitamin D analogs for obesity prevention and treatment

Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α